INTERNATIONAL PATENT: MEMORIAL SLOAN-KETTERING CANCER CENTER, SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH, MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES, TAKEDA PHARMACEUTICAL COMPANY LIMITED FILES APPLICATION FOR "BIOMARKERS AND USES THEREOF FOR TREATMENT OF CANCER WITH CD19-TARGETED ADOPTIVE CELL THERAPIES"

GENEVA, May 14 -- MEMORIAL SLOAN-KETTERING CANCER CENTER (1275 York AvenueNew York, NY 10065), SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (1275 York AvenueNew York, NY 10065), MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES (1275 York AvenueNew York, NY 10065), TAKEDA PHARMACEUTICAL COMPANY LIMITED (1-1, Doshomachi 4-chome, Chuo-kuOsaka) filed a patent application (PCT/US2024/053498) for "BIOMARKERS AND USES THEREOF FOR TREATMENT OF CANCER WITH CD19-TARGETED ADOPTIVE CELL THERAPIES" on Oct 30, 2024. With publication no. WO/2025/096493, the details related to the patent application was published on May 08, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by ...